Cas no 112188-16-6 (Des(2-Hydroxypropyl) Gadoteridol)
Des(2-Hydroxypropyl) Gadoteridol Chemical and Physical Properties
Names and Identifiers
-
- Gadolinium,[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-kN1,kN4,kN7,kN10,kO1,kO4,kO7]-
- gadolinium(III) 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid
- (1,4,7,10-Tetraazacyclododecane-1,4,7-triacetato(3-)-N1,N4,N7,N10,O1,O4,O7)gadolinium
- 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid monogadolinium salt
- Des(2-hydroxypropyl) gadoteridol
- Gd-DO 3A
- Gadolinium(III) 2,2',2''-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
- Gadolinium, [1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-kappaN1,kappaN4,kappaN7,kappaN10,kappaO1,kappaO4,kappaO7]-
- Gadolinium 1,4,7,10-tetraazacyclododecane-1,4,7-triacetate
- (1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, MONOGADOLINIUM SALT)
- 2-[4,7-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+)
- SCHEMBL1052374
- Gadolinium(III)2,2',2''-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
- [1,4,7,10-Tetraazacyclododecane-1,4,7-triacetato(3-)-kappaN1,kappaN4,kappaN7,kappaN10,kappaO1,kappaO4,kappaO7]gadolinium
- 112188-16-6
- 2-(4,7-BIS(CARBOXYLATOMETHYL)-1,4,7,10-TETRAZACYCLODODEC-1-YL)ACETATEGADOLINIUM(3+)
- Gadobutrol Impurity 3
- MOLI000606
- 3JHB4H1GFV
- Des(2-Hydroxypropyl) Gadoteridol
-
- Inchi： 1S/C14H26N4O6.Gd/c19-12(20)9-16-3-1-15-2-4-17(10-13(21)22)6-8-18(7-5-16)11-14(23)24;/h15H,1-11H2,(H,19,20)(H,21,22)(H,23,24);/q;+3/p-3
- InChI Key： SGPXHPCSEYUXPA-UHFFFAOYSA-K
- SMILES： [Gd+3].[O-]C(CN1CCN(CC(=O)[O-])CCNCCN(CC(=O)[O-])CC1)=O
Computed Properties
- Exact Mass: 501.08600
- Monoisotopic Mass: 501.086
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 10
- Heavy Atom Count: 25
- Rotatable Bond Count: 3
- Complexity: 387
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 142A^2
Experimental Properties
- Density: g/cm3
- Melting Point: >225 deg C
- Boiling Point: 617.6°Cat760mmHg
- Flash Point: 327.3°C
- PSA: 142.14000
- LogP: -6.11220
Des(2-Hydroxypropyl) Gadoteridol Security Information
- Signal Word：warning
- Hazard Statement： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- Warning Statement： P264+P280+P305+P351+P338+P337+P313
- Hazardous Material transportation number：NONH for all modes of transport
- Safety Instruction： H303+H313+H333
- Storage Condition：storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)
Des(2-Hydroxypropyl) Gadoteridol Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | D290340-10mg |
Des(2-Hydroxypropyl) Gadoteridol |
112188-16-6 | 10mg |
$ 249.00 | 2023-09-08 | ||
| TRC | D290340-25mg |
Des(2-Hydroxypropyl) Gadoteridol |
112188-16-6 | 25mg |
$ 500.00 | 2023-09-08 | ||
| TRC | D290340-50mg |
Des(2-Hydroxypropyl) Gadoteridol |
112188-16-6 | 50mg |
$ 822.00 | 2023-09-08 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 1287653-50MG |
Gadoteridol Related Compound B |
112188-16-6 | United States Pharmacopeia (USP) Reference Standard | 50MG |
￥13963.35 | 2022-02-21 | |
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 1287653-50MG |
112188-16-6 | 50MG |
￥14821.96 | 2023-01-05 | |||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 1287653-50MG |
112188-16-6 | 50MG |
￥10636.77 | 2023-04-13 |
Des(2-Hydroxypropyl) Gadoteridol Related Literature
-
Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
-
Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
-
Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
-
Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
-
Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
Additional information on Des(2-Hydroxypropyl) Gadoteridol
Research Briefing on Des(2-Hydroxypropyl) Gadoteridol (CAS: 112188-16-6): Recent Advances and Applications
Des(2-Hydroxypropyl) Gadoteridol (CAS: 112188-16-6) is a derivative of the widely used gadolinium-based contrast agent (GBCA), Gadoteridol. This compound has garnered significant attention in recent years due to its potential applications in magnetic resonance imaging (MRI) and its improved safety profile compared to traditional GBCAs. Recent studies have focused on optimizing its pharmacokinetic properties, reducing gadolinium retention in tissues, and exploring novel diagnostic and therapeutic applications. This briefing provides an overview of the latest research developments related to Des(2-Hydroxypropyl) Gadoteridol, highlighting key findings and future directions.
One of the primary motivations behind the development of Des(2-Hydroxypropyl) Gadoteridol is the growing concern over gadolinium deposition in the brain and other tissues following repeated administration of GBCAs. Studies have shown that this modified compound exhibits reduced gadolinium retention while maintaining high relaxivity, a critical factor for effective MRI contrast. Recent preclinical evaluations have demonstrated its enhanced safety profile, with minimal accumulation in the brain and kidneys, making it a promising candidate for clinical use in patients requiring multiple MRI scans.
In addition to its improved safety, Des(2-Hydroxypropyl) Gadoteridol has been investigated for its potential in targeted imaging. Researchers have explored its conjugation with various biomolecules to enable specific tissue or disease targeting. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported the successful conjugation of Des(2-Hydroxypropyl) Gadoteridol with a tumor-specific peptide, resulting in enhanced contrast in tumor-bearing mouse models. This approach opens new avenues for precision diagnostics and could significantly improve the detection of early-stage malignancies.
Another area of active research is the development of multifunctional agents based on Des(2-Hydroxypropyl) Gadoteridol. Recent work has focused on combining its imaging capabilities with therapeutic payloads, such as chemotherapeutic drugs or radionuclides. A 2024 study in Advanced Healthcare Materials detailed the synthesis of a theranostic nanoparticle incorporating Des(2-Hydroxypropyl) Gadoteridol, which demonstrated simultaneous MRI contrast enhancement and controlled drug release in response to tumor microenvironment stimuli. Such innovations hold great promise for personalized medicine and integrated diagnostic-therapeutic approaches.
Despite these advancements, challenges remain in the clinical translation of Des(2-Hydroxypropyl) Gadoteridol. Regulatory considerations, large-scale synthesis, and comprehensive toxicity studies are critical steps that need to be addressed. However, the compound's unique properties and versatility position it as a valuable tool in the evolving landscape of contrast-enhanced imaging and theranostics. Future research is expected to focus on further optimizing its chemical structure, expanding its applications, and conducting rigorous clinical trials to validate its efficacy and safety in human subjects.
112188-16-6 (Des(2-Hydroxypropyl) Gadoteridol) Related Products
- 25102-12-9(DipotassiuM Dihydrogen EthylenediaMinetetraacetate Dihydrate)
- 869-52-3(3,6,9,12-Tetraazatetradecanedioic acid, 3,6,9,12-tetrakis(carboxymethyl)-)
- 17572-97-3(Tripotassium hydrogen ethylenediaminetetraacetate)
- 67-43-6(Pentetic acid)
- 65501-24-8(Ethylenediaminetetraacetic acid tripotassium salt dihydrate)
- 2001-94-7(Edetate dipotassium)
- 6381-92-6(Ethylenediaminetetraacetic acid disodium dihydrate)
- 304675-80-7(Diammonium Ethylenediaminetetraacetate Monohydrate)
- 20824-56-0(Ethylenediaminetetraacetic Acid Diammonium Salt)
- 15251-22-6(Acetic acid-d,(ethylenedinitrilo)tetra- (8CI))
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
